Loading…

LC–MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort

Although hepatocellular carcinoma (HCC) has been subjected to continuous investigation and its symptoms are well-known, early stage diagnosis of this disease remains difficult and the survival rate after diagnosis is typically very low (3–5%). Early and accurate detection of metabolic changes in the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of proteome research 2012-12, Vol.11 (12), p.5914-5923
Main Authors: Xiao, Jun Feng, Varghese, Rency S, Zhou, Bin, Nezami Ranjbar, Mohammad R, Zhao, Yi, Tsai, Tsung-Heng, Di Poto, Cristina, Wang, Jinlian, Goerlitz, David, Luo, Yue, Cheema, Amrita K, Sarhan, Naglaa, Soliman, Hanan, Tadesse, Mahlet G, Ziada, Dina Hazem, Ressom, Habtom W
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a471t-3ac649bb5e8b8fe9761f4ae2fc7107204bb6033b1f41877ad9710b4a127fc6823
cites cdi_FETCH-LOGICAL-a471t-3ac649bb5e8b8fe9761f4ae2fc7107204bb6033b1f41877ad9710b4a127fc6823
container_end_page 5923
container_issue 12
container_start_page 5914
container_title Journal of proteome research
container_volume 11
creator Xiao, Jun Feng
Varghese, Rency S
Zhou, Bin
Nezami Ranjbar, Mohammad R
Zhao, Yi
Tsai, Tsung-Heng
Di Poto, Cristina
Wang, Jinlian
Goerlitz, David
Luo, Yue
Cheema, Amrita K
Sarhan, Naglaa
Soliman, Hanan
Tadesse, Mahlet G
Ziada, Dina Hazem
Ressom, Habtom W
description Although hepatocellular carcinoma (HCC) has been subjected to continuous investigation and its symptoms are well-known, early stage diagnosis of this disease remains difficult and the survival rate after diagnosis is typically very low (3–5%). Early and accurate detection of metabolic changes in the sera of patients with liver cirrhosis can help improve the prognosis of HCC and lead to a better understanding of its mechanism at the molecular level, thus providing patients with in-time treatment of the disease. In this study, we compared metabolite levels in sera of 40 HCC patients and 49 cirrhosis patients from Egypt by using ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometer (UPLC-QTOF MS). Following data preprocessing, the most relevant ions in distinguishing HCC cases from cirrhotic controls are selected by statistical methods. Putative metabolite identifications for these ions are obtained through mass-based database search. The identities of some of the putative identifications are verified by comparing their MS/MS fragmentation patterns and retention times with those from authentic compounds. Finally, the serum samples are reanalyzed for quantitation of selected metabolites as candidate biomarkers of HCC. This quantitation was performed using isotope dilution by selected reaction monitoring (SRM) on a triple quadrupole linear ion trap (QqQLIT) coupled to UPLC. Statistical analysis of the UPLC-QTOF data identified 274 monoisotopic ion masses with statistically significant differences in ion intensities between HCC cases and cirrhotic controls. Putative identifications were obtained for 158 ions by mass based search against databases. We verified the identities of selected putative identifications including glycholic acid (GCA), glycodeoxycholic acid (GDCA), 3β, 6β-dihydroxy-5β-cholan-24-oic acid, oleoyl carnitine, and Phe-Phe. SRM-based quantitation confirmed significant differences between HCC and cirrhotic controls in metabolite levels of bile acid metabolites, long chain carnitines and small peptide. Our study provides useful insight into appropriate experimental design and computational methods for serum biomarker discovery using LC–MS/MS based metabolomics. This study has led to the identification of candidate biomarkers with significant changes in metabolite levels between HCC cases and cirrhotic controls. This is the first MS-based metabolic biomarker discovery study on Egyptian subjects that led to
doi_str_mv 10.1021/pr300673x
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3719870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1237510075</sourcerecordid><originalsourceid>FETCH-LOGICAL-a471t-3ac649bb5e8b8fe9761f4ae2fc7107204bb6033b1f41877ad9710b4a127fc6823</originalsourceid><addsrcrecordid>eNptkc1KxDAUhYMo_owufAHJRtDFaNK0TbsRnOIfjLhQ1-Emk2i0bWrSiu58B9_QJzEyOii4yQ33fpyc3IPQNiUHlCT0sPOMkJyzlyW0TjOWjVlJ-PLPvSjZGtoI4YEQmnHCVtFawggvKM_WUTOtPt7eL6_xBIKe4WvthwZf6h6kq11jVcDGeXwx021vjVXQW9diZ_C57qB3Stf1UIPHFXhlW9cAnth4-kftA7YtPrl77XoLLa7cvfP9JloxUAe99V1H6Pb05KY6H0-vzi6q4-kYUk77MQOVp6WUmS5kYXTJc2pS0IlRnBKekFTKnDAmY5cWnMOsjH2ZAk24UXmRsBE6mut2g2z0TEX3HmrReRu9vQoHVvydtPZe3LlnwTgti7ijEdr7FvDuadChF40NX7-FVrshCJownlFCeBbR_TmqvAvBa7N4hhLxFY9YxBPZnd--FuRPHhHYnQOggnhwg2_jmv4R-gQxGJmC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1237510075</pqid></control><display><type>article</type><title>LC–MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Xiao, Jun Feng ; Varghese, Rency S ; Zhou, Bin ; Nezami Ranjbar, Mohammad R ; Zhao, Yi ; Tsai, Tsung-Heng ; Di Poto, Cristina ; Wang, Jinlian ; Goerlitz, David ; Luo, Yue ; Cheema, Amrita K ; Sarhan, Naglaa ; Soliman, Hanan ; Tadesse, Mahlet G ; Ziada, Dina Hazem ; Ressom, Habtom W</creator><creatorcontrib>Xiao, Jun Feng ; Varghese, Rency S ; Zhou, Bin ; Nezami Ranjbar, Mohammad R ; Zhao, Yi ; Tsai, Tsung-Heng ; Di Poto, Cristina ; Wang, Jinlian ; Goerlitz, David ; Luo, Yue ; Cheema, Amrita K ; Sarhan, Naglaa ; Soliman, Hanan ; Tadesse, Mahlet G ; Ziada, Dina Hazem ; Ressom, Habtom W</creatorcontrib><description>Although hepatocellular carcinoma (HCC) has been subjected to continuous investigation and its symptoms are well-known, early stage diagnosis of this disease remains difficult and the survival rate after diagnosis is typically very low (3–5%). Early and accurate detection of metabolic changes in the sera of patients with liver cirrhosis can help improve the prognosis of HCC and lead to a better understanding of its mechanism at the molecular level, thus providing patients with in-time treatment of the disease. In this study, we compared metabolite levels in sera of 40 HCC patients and 49 cirrhosis patients from Egypt by using ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometer (UPLC-QTOF MS). Following data preprocessing, the most relevant ions in distinguishing HCC cases from cirrhotic controls are selected by statistical methods. Putative metabolite identifications for these ions are obtained through mass-based database search. The identities of some of the putative identifications are verified by comparing their MS/MS fragmentation patterns and retention times with those from authentic compounds. Finally, the serum samples are reanalyzed for quantitation of selected metabolites as candidate biomarkers of HCC. This quantitation was performed using isotope dilution by selected reaction monitoring (SRM) on a triple quadrupole linear ion trap (QqQLIT) coupled to UPLC. Statistical analysis of the UPLC-QTOF data identified 274 monoisotopic ion masses with statistically significant differences in ion intensities between HCC cases and cirrhotic controls. Putative identifications were obtained for 158 ions by mass based search against databases. We verified the identities of selected putative identifications including glycholic acid (GCA), glycodeoxycholic acid (GDCA), 3β, 6β-dihydroxy-5β-cholan-24-oic acid, oleoyl carnitine, and Phe-Phe. SRM-based quantitation confirmed significant differences between HCC and cirrhotic controls in metabolite levels of bile acid metabolites, long chain carnitines and small peptide. Our study provides useful insight into appropriate experimental design and computational methods for serum biomarker discovery using LC–MS/MS based metabolomics. This study has led to the identification of candidate biomarkers with significant changes in metabolite levels between HCC cases and cirrhotic controls. This is the first MS-based metabolic biomarker discovery study on Egyptian subjects that led to the identification of candidate metabolites that discriminate early stage HCC from patients with liver cirrhosis.</description><identifier>ISSN: 1535-3893</identifier><identifier>EISSN: 1535-3907</identifier><identifier>DOI: 10.1021/pr300673x</identifier><identifier>PMID: 23078175</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Biomarkers, Tumor - blood ; Carcinoma, Hepatocellular - diagnosis ; Carcinoma, Hepatocellular - metabolism ; Case-Control Studies ; Chromatography, Liquid - methods ; Computational Biology - methods ; Egypt ; Female ; Humans ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - metabolism ; Liver Neoplasms - diagnosis ; Liver Neoplasms - metabolism ; Male ; Metabolome ; Metabolomics - methods ; Middle Aged ; Neoplasm Staging - methods ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods</subject><ispartof>Journal of proteome research, 2012-12, Vol.11 (12), p.5914-5923</ispartof><rights>Copyright © 2012 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a471t-3ac649bb5e8b8fe9761f4ae2fc7107204bb6033b1f41877ad9710b4a127fc6823</citedby><cites>FETCH-LOGICAL-a471t-3ac649bb5e8b8fe9761f4ae2fc7107204bb6033b1f41877ad9710b4a127fc6823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23078175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xiao, Jun Feng</creatorcontrib><creatorcontrib>Varghese, Rency S</creatorcontrib><creatorcontrib>Zhou, Bin</creatorcontrib><creatorcontrib>Nezami Ranjbar, Mohammad R</creatorcontrib><creatorcontrib>Zhao, Yi</creatorcontrib><creatorcontrib>Tsai, Tsung-Heng</creatorcontrib><creatorcontrib>Di Poto, Cristina</creatorcontrib><creatorcontrib>Wang, Jinlian</creatorcontrib><creatorcontrib>Goerlitz, David</creatorcontrib><creatorcontrib>Luo, Yue</creatorcontrib><creatorcontrib>Cheema, Amrita K</creatorcontrib><creatorcontrib>Sarhan, Naglaa</creatorcontrib><creatorcontrib>Soliman, Hanan</creatorcontrib><creatorcontrib>Tadesse, Mahlet G</creatorcontrib><creatorcontrib>Ziada, Dina Hazem</creatorcontrib><creatorcontrib>Ressom, Habtom W</creatorcontrib><title>LC–MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort</title><title>Journal of proteome research</title><addtitle>J. Proteome Res</addtitle><description>Although hepatocellular carcinoma (HCC) has been subjected to continuous investigation and its symptoms are well-known, early stage diagnosis of this disease remains difficult and the survival rate after diagnosis is typically very low (3–5%). Early and accurate detection of metabolic changes in the sera of patients with liver cirrhosis can help improve the prognosis of HCC and lead to a better understanding of its mechanism at the molecular level, thus providing patients with in-time treatment of the disease. In this study, we compared metabolite levels in sera of 40 HCC patients and 49 cirrhosis patients from Egypt by using ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometer (UPLC-QTOF MS). Following data preprocessing, the most relevant ions in distinguishing HCC cases from cirrhotic controls are selected by statistical methods. Putative metabolite identifications for these ions are obtained through mass-based database search. The identities of some of the putative identifications are verified by comparing their MS/MS fragmentation patterns and retention times with those from authentic compounds. Finally, the serum samples are reanalyzed for quantitation of selected metabolites as candidate biomarkers of HCC. This quantitation was performed using isotope dilution by selected reaction monitoring (SRM) on a triple quadrupole linear ion trap (QqQLIT) coupled to UPLC. Statistical analysis of the UPLC-QTOF data identified 274 monoisotopic ion masses with statistically significant differences in ion intensities between HCC cases and cirrhotic controls. Putative identifications were obtained for 158 ions by mass based search against databases. We verified the identities of selected putative identifications including glycholic acid (GCA), glycodeoxycholic acid (GDCA), 3β, 6β-dihydroxy-5β-cholan-24-oic acid, oleoyl carnitine, and Phe-Phe. SRM-based quantitation confirmed significant differences between HCC and cirrhotic controls in metabolite levels of bile acid metabolites, long chain carnitines and small peptide. Our study provides useful insight into appropriate experimental design and computational methods for serum biomarker discovery using LC–MS/MS based metabolomics. This study has led to the identification of candidate biomarkers with significant changes in metabolite levels between HCC cases and cirrhotic controls. This is the first MS-based metabolic biomarker discovery study on Egyptian subjects that led to the identification of candidate metabolites that discriminate early stage HCC from patients with liver cirrhosis.</description><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Hepatocellular - diagnosis</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Case-Control Studies</subject><subject>Chromatography, Liquid - methods</subject><subject>Computational Biology - methods</subject><subject>Egypt</subject><subject>Female</subject><subject>Humans</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - metabolism</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - metabolism</subject><subject>Male</subject><subject>Metabolome</subject><subject>Metabolomics - methods</subject><subject>Middle Aged</subject><subject>Neoplasm Staging - methods</subject><subject>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods</subject><issn>1535-3893</issn><issn>1535-3907</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNptkc1KxDAUhYMo_owufAHJRtDFaNK0TbsRnOIfjLhQ1-Emk2i0bWrSiu58B9_QJzEyOii4yQ33fpyc3IPQNiUHlCT0sPOMkJyzlyW0TjOWjVlJ-PLPvSjZGtoI4YEQmnHCVtFawggvKM_WUTOtPt7eL6_xBIKe4WvthwZf6h6kq11jVcDGeXwx021vjVXQW9diZ_C57qB3Stf1UIPHFXhlW9cAnth4-kftA7YtPrl77XoLLa7cvfP9JloxUAe99V1H6Pb05KY6H0-vzi6q4-kYUk77MQOVp6WUmS5kYXTJc2pS0IlRnBKekFTKnDAmY5cWnMOsjH2ZAk24UXmRsBE6mut2g2z0TEX3HmrReRu9vQoHVvydtPZe3LlnwTgti7ijEdr7FvDuadChF40NX7-FVrshCJownlFCeBbR_TmqvAvBa7N4hhLxFY9YxBPZnd--FuRPHhHYnQOggnhwg2_jmv4R-gQxGJmC</recordid><startdate>20121207</startdate><enddate>20121207</enddate><creator>Xiao, Jun Feng</creator><creator>Varghese, Rency S</creator><creator>Zhou, Bin</creator><creator>Nezami Ranjbar, Mohammad R</creator><creator>Zhao, Yi</creator><creator>Tsai, Tsung-Heng</creator><creator>Di Poto, Cristina</creator><creator>Wang, Jinlian</creator><creator>Goerlitz, David</creator><creator>Luo, Yue</creator><creator>Cheema, Amrita K</creator><creator>Sarhan, Naglaa</creator><creator>Soliman, Hanan</creator><creator>Tadesse, Mahlet G</creator><creator>Ziada, Dina Hazem</creator><creator>Ressom, Habtom W</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20121207</creationdate><title>LC–MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort</title><author>Xiao, Jun Feng ; Varghese, Rency S ; Zhou, Bin ; Nezami Ranjbar, Mohammad R ; Zhao, Yi ; Tsai, Tsung-Heng ; Di Poto, Cristina ; Wang, Jinlian ; Goerlitz, David ; Luo, Yue ; Cheema, Amrita K ; Sarhan, Naglaa ; Soliman, Hanan ; Tadesse, Mahlet G ; Ziada, Dina Hazem ; Ressom, Habtom W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a471t-3ac649bb5e8b8fe9761f4ae2fc7107204bb6033b1f41877ad9710b4a127fc6823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Hepatocellular - diagnosis</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Case-Control Studies</topic><topic>Chromatography, Liquid - methods</topic><topic>Computational Biology - methods</topic><topic>Egypt</topic><topic>Female</topic><topic>Humans</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - metabolism</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - metabolism</topic><topic>Male</topic><topic>Metabolome</topic><topic>Metabolomics - methods</topic><topic>Middle Aged</topic><topic>Neoplasm Staging - methods</topic><topic>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xiao, Jun Feng</creatorcontrib><creatorcontrib>Varghese, Rency S</creatorcontrib><creatorcontrib>Zhou, Bin</creatorcontrib><creatorcontrib>Nezami Ranjbar, Mohammad R</creatorcontrib><creatorcontrib>Zhao, Yi</creatorcontrib><creatorcontrib>Tsai, Tsung-Heng</creatorcontrib><creatorcontrib>Di Poto, Cristina</creatorcontrib><creatorcontrib>Wang, Jinlian</creatorcontrib><creatorcontrib>Goerlitz, David</creatorcontrib><creatorcontrib>Luo, Yue</creatorcontrib><creatorcontrib>Cheema, Amrita K</creatorcontrib><creatorcontrib>Sarhan, Naglaa</creatorcontrib><creatorcontrib>Soliman, Hanan</creatorcontrib><creatorcontrib>Tadesse, Mahlet G</creatorcontrib><creatorcontrib>Ziada, Dina Hazem</creatorcontrib><creatorcontrib>Ressom, Habtom W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of proteome research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xiao, Jun Feng</au><au>Varghese, Rency S</au><au>Zhou, Bin</au><au>Nezami Ranjbar, Mohammad R</au><au>Zhao, Yi</au><au>Tsai, Tsung-Heng</au><au>Di Poto, Cristina</au><au>Wang, Jinlian</au><au>Goerlitz, David</au><au>Luo, Yue</au><au>Cheema, Amrita K</au><au>Sarhan, Naglaa</au><au>Soliman, Hanan</au><au>Tadesse, Mahlet G</au><au>Ziada, Dina Hazem</au><au>Ressom, Habtom W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LC–MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort</atitle><jtitle>Journal of proteome research</jtitle><addtitle>J. Proteome Res</addtitle><date>2012-12-07</date><risdate>2012</risdate><volume>11</volume><issue>12</issue><spage>5914</spage><epage>5923</epage><pages>5914-5923</pages><issn>1535-3893</issn><eissn>1535-3907</eissn><abstract>Although hepatocellular carcinoma (HCC) has been subjected to continuous investigation and its symptoms are well-known, early stage diagnosis of this disease remains difficult and the survival rate after diagnosis is typically very low (3–5%). Early and accurate detection of metabolic changes in the sera of patients with liver cirrhosis can help improve the prognosis of HCC and lead to a better understanding of its mechanism at the molecular level, thus providing patients with in-time treatment of the disease. In this study, we compared metabolite levels in sera of 40 HCC patients and 49 cirrhosis patients from Egypt by using ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometer (UPLC-QTOF MS). Following data preprocessing, the most relevant ions in distinguishing HCC cases from cirrhotic controls are selected by statistical methods. Putative metabolite identifications for these ions are obtained through mass-based database search. The identities of some of the putative identifications are verified by comparing their MS/MS fragmentation patterns and retention times with those from authentic compounds. Finally, the serum samples are reanalyzed for quantitation of selected metabolites as candidate biomarkers of HCC. This quantitation was performed using isotope dilution by selected reaction monitoring (SRM) on a triple quadrupole linear ion trap (QqQLIT) coupled to UPLC. Statistical analysis of the UPLC-QTOF data identified 274 monoisotopic ion masses with statistically significant differences in ion intensities between HCC cases and cirrhotic controls. Putative identifications were obtained for 158 ions by mass based search against databases. We verified the identities of selected putative identifications including glycholic acid (GCA), glycodeoxycholic acid (GDCA), 3β, 6β-dihydroxy-5β-cholan-24-oic acid, oleoyl carnitine, and Phe-Phe. SRM-based quantitation confirmed significant differences between HCC and cirrhotic controls in metabolite levels of bile acid metabolites, long chain carnitines and small peptide. Our study provides useful insight into appropriate experimental design and computational methods for serum biomarker discovery using LC–MS/MS based metabolomics. This study has led to the identification of candidate biomarkers with significant changes in metabolite levels between HCC cases and cirrhotic controls. This is the first MS-based metabolic biomarker discovery study on Egyptian subjects that led to the identification of candidate metabolites that discriminate early stage HCC from patients with liver cirrhosis.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>23078175</pmid><doi>10.1021/pr300673x</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1535-3893
ispartof Journal of proteome research, 2012-12, Vol.11 (12), p.5914-5923
issn 1535-3893
1535-3907
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3719870
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Biomarkers, Tumor - blood
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - metabolism
Case-Control Studies
Chromatography, Liquid - methods
Computational Biology - methods
Egypt
Female
Humans
Liver Cirrhosis - diagnosis
Liver Cirrhosis - metabolism
Liver Neoplasms - diagnosis
Liver Neoplasms - metabolism
Male
Metabolome
Metabolomics - methods
Middle Aged
Neoplasm Staging - methods
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods
title LC–MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A41%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LC%E2%80%93MS%20Based%20Serum%20Metabolomics%20for%20Identification%20of%20Hepatocellular%20Carcinoma%20Biomarkers%20in%20Egyptian%20Cohort&rft.jtitle=Journal%20of%20proteome%20research&rft.au=Xiao,%20Jun%20Feng&rft.date=2012-12-07&rft.volume=11&rft.issue=12&rft.spage=5914&rft.epage=5923&rft.pages=5914-5923&rft.issn=1535-3893&rft.eissn=1535-3907&rft_id=info:doi/10.1021/pr300673x&rft_dat=%3Cproquest_pubme%3E1237510075%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a471t-3ac649bb5e8b8fe9761f4ae2fc7107204bb6033b1f41877ad9710b4a127fc6823%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1237510075&rft_id=info:pmid/23078175&rfr_iscdi=true